The first novel coronavirus pneumonia was approved or marketed to treat new crown pneumonia in China

Sorting out Pinellia Recently, Haizheng pharmaceutical's fabiravir tablet was officially approved by the State Food and Drug Administration for drug registration According to the data of the State Food and drug administration, the imitative drug of Haizheng Pharmaceutical Co., Ltd fapiravir has been approved for marketing, and the indication is for the treatment of new or recurrent influenza in adults (only used when other anti influenza drugs are ineffective or ineffective) That is to say novel coronavirus pneumonia is still expanding in indications Novel coronavirus pneumonia is one of the drugs currently focusing on the potential of new crown pneumonia in Zhang Xinmin, director of the Biotechnology Department's Center for biological defense at the press conference of the joint defense and joint control mechanism of the State Council, held in February 15th At the meeting, Wu Yuanbin, director of the Department of social development and science and technology of the Ministry of science and technology, also said that fabiravir is an overseas listed drug for the treatment of influenza At present, clinical trials have been carried out in Shenzhen, with more than 70 patients in the group, including the control group, initially showing relatively obvious efficacy and low adverse reactions On the 3rd to 4th day after treatment, the negative rate of viral nucleic acid in the treatment group was significantly higher than that in the control group China's novel coronavirus pneumonia trial was conducted by ClinicalTrials.gov and the China Clinical Trial Registration Center (ChiCTR) in February 15th 3 clinical trials have been conducted for the treatment of new crown pneumonia Two of them are led by the First Affiliated Hospital of Zhejiang University Medical College, and the other is in the charge of Shenzhen Third People's hospital Regarding whether novel coronavirus pneumonia novel coronavirus can be used for treatment, Li Yue, head of the Department of medicine, Hai Zheng pharmaceutical, said in a media interview that the clinical efficacy of the new formula coronavirus should be further verified He said that the novel coronavirus pneumonia study is only a trial drug, and only a small number of patients in the country have used it Its therapeutic effect needs further experimental verification However, novel coronavirus can effectively reduce the viral load of the new coronavirus infection and effectively inhibit the replication of the viral genome according to the in vitro activity test data of the Military Medical Research Institute At all concentrations, fabiravir did not change cell viability, that is, it had no toxic effect on cells Fabiravir is a new broad-spectrum anti RNA virus drug, and the new coronavirus belongs to RNA single chain virus It was first developed by Japan Fushan Chemical Industry Co., Ltd and applied for the first compound patent of fabiravir on August 18, 1999 The drug was approved for marketing in Japan in March 2014 for antiviral treatment of influenza A and B In addition to influenza virus, the drug also showed good antiviral effect on a variety of RNA viruses, such as Ebola virus, sand virus, Bunia virus, rabies virus, etc.